Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed B7-H3 targeting ADC (R&D code: 7MW3711) has been approved by the NMPA to initiate clinical trials in combination with a PD-1/VEGF bispecific antibody (Junshi Biosciences R&D code: JS207), with or without platinum-based chemotherapy (cisplatin or carboplatin), for patients with advanced solid tumors.

7MW3711 is a novel B7-H3-targeting ADC developed by Mabwell’s IDDC™ platform. It has been approved to conduct clinical trials for advanced solid tumors in both China and the United States, and has been granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of small cell lung cancer. Publicly disclosed clinical data show that it has a tolerable safety profile and good anti-tumor activity in patients with advanced tumors including lung cancer and esophageal cancer.